Delcath Systems (DCTH) Reports Q4 Loss of $0.31/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/27/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
- TD Cowen: 'Sober View Suggests Structural Alcohol Risks Are Overblown'
- Needham Starts NeoVolta (NEOV) at Buy
- Hut 8 Mining Corp. (HUT) PT Raised to $55 at KBW As Management Delivers
- S&P 500 ends lower; chips tumble and Moderna rallies
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Delcath Reports 2014 Fourth Quarter And Full Year Financial Results
March 10, 2015 4:30 PM EDTNEW YORK, March 10, 2015 /PRNewswire/ --Â Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces financial results for the three and 12 months ended December 31, 2014.Â
Highlights of 2014 and recent weeks include:
Opened for enrollment a global Phase 2 clinical trial program for Melphalan/HDS for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC) or primary liver cancer at leading cancer centers in Europe and at the Moffitt Cancer... More